NADAC acquisition cost data for PROCRIT 20,000 UNITS/ML VIAL. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 59676032004 | $520.60 | 2021-06-23 | Rx |
| 59676032004 | $520.60 | 2021-06-23 | Rx |
| 59676032004 | $520.60 | 2021-06-23 | Rx |
| 59676032004 | $520.60 | 2021-06-23 | Rx |
| 59676032004 | $520.60 | 2021-06-23 | Rx |
| 59676032004 | $520.60 | 2021-06-23 | Rx |
| 59676032004 | $520.60 | 2021-06-23 | Rx |
| 59676032004 | $520.60 | 2021-06-23 | Rx |
| 59676032004 | $520.60 | 2021-06-23 | Rx |
| 59676032004 | $520.60 | 2021-06-23 | Rx |
Generic: Epoetin Alfa | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $174.5M | 116,925 | 26,265 | $533.30 |
| 2020 | $148.3M | 98,872 | 22,329 | $517.00 |
| 2021 | $133.9M | 85,477 | 19,692 | $516.28 |
| 2022 | $138.1M | 85,942 | 20,657 | $525.16 |
| 2023 | $163.1M | 102,354 | 24,380 | $538.47 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $41.9M | 28,287 | 7,471 |
| New York | $30.0M | 15,519 | 3,592 |
| New Jersey | $17.9M | 9,697 | 2,097 |
| Florida | $13.4M | 9,542 | 2,457 |
| Texas | $7.3M | 4,787 | 1,278 |
| Pennsylvania | $5.2M | 4,051 | 793 |
| Georgia | $3.8M | 2,096 | 435 |
| Oklahoma | $3.6M | 1,034 | 183 |
| Louisiana | $3.5M | 1,654 | 488 |
| North Carolina | $3.5M | 1,636 | 388 |
| Massachusetts | $3.2M | 2,642 | 458 |
| Michigan | $3.2M | 1,883 | 475 |
| Maryland | $2.3M | 2,299 | 485 |
| Illinois | $2.2M | 2,153 | 470 |
| Ohio | $2.0M | 1,948 | 414 |
| Alabama | $2.0M | 781 | 229 |
| Arizona | $1.9M | 796 | 218 |
| South Carolina | $1.4M | 1,238 | 308 |
| Virginia | $1.4M | 1,012 | 249 |
| Hawaii | $1.3M | 964 | 215 |
| Kentucky | $1.2M | 872 | 185 |
| Arkansas | $1.2M | 542 | 170 |
| Connecticut | $1.1M | 862 | 185 |
| Mississippi | $776.4K | 391 | 109 |
| Tennessee | $744.6K | 452 | 136 |
| Indiana | $690.7K | 544 | 132 |
| Missouri | $517.9K | 352 | 98 |
| Colorado | $481.8K | 392 | 107 |
| Washington | $466.5K | 448 | 113 |
| Wisconsin | $408.4K | 302 | 80 |
| Nevada | $403.5K | 218 | 104 |
| Delaware | $353.2K | 226 | 49 |
| District of Columbia | $346.9K | 611 | 122 |
| Iowa | $327.5K | 149 | 51 |
| Oregon | $318.1K | 230 | 67 |
| West Virginia | $307.8K | 246 | 53 |
| Alaska | $259.2K | 125 | 33 |
| Puerto Rico | $258.6K | 110 | 66 |
| New Hampshire | $245.6K | 139 | 23 |
| Minnesota | $226.7K | 173 | 40 |
| Virgin Islands | $224.6K | 73 | 12 |
| Rhode Island | $179.0K | 193 | 38 |
| Maine | $176.0K | 133 | 30 |
| Nebraska | $90.8K | 68 | 21 |
| New Mexico | $82.5K | 80 | 26 |
| Idaho | $77.2K | 59 | 11 |
| Utah | $59.9K | 63 | 27 |
| Kansas | $38.4K | 62 | 22 |
| North Dakota | $34.6K | 21 | N/A |
| Montana | $25.8K | 35 | N/A |
| Vermont | $20.3K | 17 | N/A |
| Guam | $19.7K | 17 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.